EValuating the Safety Of De-escaLated Head and Neck Irradiation in HPV positivE Oropharynx Cancer in Non-smokers/Minimal Smokers

Oropharyngeal Cancer Clinical Trial

Official title:

EValuating the Safety Of De-escaLated Head and Neck Irradiation in HPV positivE Oropharynx Cancer in Non-smokers/Minimal Smokers

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03777384
• Other study ID #: SH EVOLVE
• Status: Active, not recruiting
• Start date: October 12, 2018
• Est. completion date: December 2025

Study information

• Verified date: January 2024
• Source: Sanford Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A prospective, observational study evaluating the durability of local/regional control of previously published de-escalated radiotherapy protocols for patients with P16 positive oropharynx cancers who have minimal nicotine exposure who are not current uses (< 10 pack year smoking history; < 10 year history of any nicotine product [electronic cigarette, chewing tobacco]). Quality of Life measures will also be collected.

Description:

This is a prospective, single-site, observational study in head and neck cancer participants. The purpose of this study is to provide a systematic platform to analyze, interpret, and track radiation dose de-escalation therapy and associated participant outcomes from treatments identified by these results.

Participants will be asked to complete quality of life questionnaires at regular time points before, during, and after treatment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 75
• Est. completion date: December 2025
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years

• Histologic confirmation of tumor of the oropharynx

• Radiation therapy (de-escalated head and neck irradiation) decision has been made

• Human Papilloma Virus (HPV) associated cancer as determined by positive p16 immunohistochemistry

• HPV positivity is defined by p16 IHC staining of > 70% of tumor cells (strong and diffuse nuclear and cytoplasmic staining)

• For cases that are indeterminate or if p16 testing cannot be accurately performed, HPV positivity can be confirmed by high-risk HPV DNA Testing which covers the following HPV subtypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

• < 10 pack year smoking history OR < 10 year nicotine use history

• No current tobacco/nicotine use (including electronic cigarettes and chewing tobacco)

• T1-T3, N0-N2 (AJCC8) requiring definitive therapy greater than surgery alone

• Ability to provide informed written consent

• Willingness to return to Sanford Cancer Center for follow-up

• Life expectancy > 12 weeks

• ECOG performance status < 3 (Appendix B)

• Adequate organ function for chemotherapy and radiotherapy

Exclusion Criteria:

• Any of the following because the inclusion criteria require delivery of radiotherapy and chemotherapy which is known to be genotoxic, and is associated with mutagenic and teratogenic effects: pregnant women, nursing women, men or women of childbearing potential who are unwilling to employ adequate contraception.

• Prior head and neck radiotherapy

• Any factor precluding safe delivery of chemotherapy

Related Conditions & MeSH terms

• Oropharyngeal Cancer
• Oropharyngeal Neoplasms

Locations

Country	Name	City	State
United States	Sanford Roger Maris Cancer Center	Fargo	North Dakota
United States	Sanford Edith Cancer Center	Sioux Falls	South Dakota

Sponsors (1)

Lead Sponsor	Collaborator
Sanford Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The durability of local disease control of de-escalated radiotherapy protocols in the community cancer center setting.	Number of participants who remain disease free from the end of treatment to 5 years after treatment.	End of treatment to 5 years after end of treatment